ArticleHaematologica2019
Deep targeted sequencing of
Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- ComplexInternational journal of molecular sciences · 2026Review
- Refractory Thrombocytopenia in TP53-Aberrant Chronic Lymphocytic Leukemia: A Multimechanistic Case with Response to Idelalisib and Romiplostim.Journal of clinical medicine · 2026Article
- Detection of clinically relevant variants in theHemaSphere · 2025Article
- Cancer associated variant enrichment CAVE, a gene agnostic approach to identify low burden variants in chronic lymphocytic leukemia.Scientific reports · 2024Article
- ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.Leukemia · 2024Review
- Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.The journal of pathology. Clinical research · 2024Article
- Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL.Blood advances · 2023Article
- The Broad Spectrum ofHuman mutation · 2023Article
- Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2022Review
- TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.American journal of hematology · 2022Article
- Article
- Impact of Low-BurdenFrontiers in oncology · 2022Review
- Landscape of TP53 Alterations in Chronic Lymphocytic LeukemiaFrontiers in oncology · 2022Review
- Article
- Clinical Outcomes in Patients with Multi-HitClinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study.Haematologica · 2021Article
- Validating genomic tools for precision medicine in chronic lymphocytic leukemia: ERIC leads the way.Haematologica · 2021Article
- Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients.Scientific reports · 2020Observational
- Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects.OncoTargets and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In chronic lymphocytic leukemia,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.